Heavy Metals: What's Really Inside Your Body
Mercury, lead, arsenic, cadmium, aluminum: sources, mechanisms, diagnostics, and the logic of a medical detoxification.
Special Focus at Vivecura: Heavy-Metal Diagnostics & Chelation Therapy
Heavy-metal detoxification is one of my four core areas, alongside Gut Reset, Mold Therapy, and ketamine-assisted treatment. I work with the DMPS provocation test according to the protocol of the German Medical Society for Metal Toxicology (Ärztliche Gesellschaft für Metalltoxikologie) and conduct structured chelation-therapy cycles with full mineral monitoring.
Why I take this topic so seriously
Chronic exhaustion. Brain fog that no amount of sleep can clear. Muscle pain with no orthopedic findings. Mood swings without a psychiatric cause. Hormonal imbalances that fail to respond to any therapy. And, again and again, the same sentence: "Your blood values are unremarkable."
In such cases, when patients come who have already tried a great deal, whose lab values look fine on paper, and whose suffering is nonetheless real, the next question I ask myself is: Which environmental toxins have never been measured?
Heavy metals sit right at the top of that list. Not because they are always the cause, but because they are systematically under-tested, and because the difference between a standard blood test and genuine tissue diagnostics is fundamental.
Over years in my practice I have made a consistent observation: in patients who do not respond to classical and functional therapies, or who respond only briefly, DMPS provocation tests reveal elevated mobilizable mercury amounts in a notable number of cases, even when spontaneous urinary values were entirely unremarkable. Under the influence of a chelator, the body releases metals that it would not mobilize on its own. That is precisely the diagnostic value of this procedure.
What is particularly striking: patients whose amalgam fillings were removed 10, 15, or 20 years ago, often without adequate protective measures, frequently still carry relevant mobilizable amounts. That is not coincidence. That is half-life mathematics. The mercury isn't gone just because the filling is gone.
Mercury, the best known of the heavy metals
What mercury does inside cells, the mechanism
Mercury binds with extreme affinity to sulfhydryl groups (–SH). These are found in cysteine residues of vital enzymes, in glutathione, and in the selenocysteine residues of selenoproteins. The binding is nearly irreversible, which explains why mercury can affect so many different organ systems simultaneously: wherever sulfhydryl-bearing enzymes occupy critical control points, mercury can intervene.
Blocked enzymes, what this means in everyday life
- Glutathione peroxidase: Primary antioxidant enzyme → inhibition → oxidative stress, cell-membrane damage, accelerated aging at the cellular level
- Thioredoxin reductase: Key enzyme for selenoprotein function. Hg binds selenocysteine with 10⁶-fold higher affinity than cysteine → functional selenium deficiency, even when blood selenium appears normal
- Mn-superoxide dismutase (Mn-SOD): Mitochondrial antioxidant → blockade promotes mitochondrial damage and chronic exhaustion at the cellular level
- Respiratory chain (complexes I, II, III): Direct disruption of energy production → ATP deficit → fatigue, cold intolerance, cognitive slowing
- Neuregulin and BDNF signaling: Hg disrupts synaptic plasticity and growth factors → brain fog, mood instability, cognitive decline
Why genetic susceptibility is so decisive
Not everyone responds the same way to the same exposure. Polymorphisms in the genes CPOX4 (coproporphyrinogen oxidase), SLC6A4 (serotonin transporter), and MT1M/MT2A (metallothioneins) substantially modulate individual susceptibility. In the NIH-funded Casa Pia data, mercury exposure in boys carrying the SLC6A4 deletion allele explained up to 17.5% of the variance in a memory test, versus only 1.1% in wild-type boys. At population level, no effect. In the genetically defined subgroup, unmistakable.
That explains the apparent contradiction: the person at the next table with similarly many amalgam fillings has no symptoms because they carry different metallothionein polymorphisms, are better supplied with selenium, or carry less systemic stress. That is biology, not imagination.
Methylmercury from fish, the underestimated everyday problem
Most of the people I test for heavy metals no longer have any amalgam. And yet we still find mobilizable mercury. The most commonly overlooked cause: regular consumption of tuna, swordfish, or other large predatory fish.
Methylmercury is the organic form of mercury, which is enriched in marine food chains through biomagnification. A tuna at the top of the food chain concentrates the mercury from thousands of smaller fish, up to one million times higher than the concentration in the surrounding water. The problem: methylmercury crosses the blood-brain barrier using a trick that inorganic mercury cannot exploit.
In the bloodstream, methylmercury binds the amino acid cysteine to form a complex that structurally resembles the amino acid methionine. The L-type amino-acid transporter (LAT1) at the blood-brain barrier, which normally ferries methionine and leucine into the brain, recognizes this complex and actively shuttles it through. Inorganic mercury has no such transport route; it must diffuse passively and does so far less efficiently. That makes methylmercury from fish neurobiologically more aggressive than the mercury vapor from amalgam.
Which fish are safe, and which are not?
The FDA has analyzed more than 1,300 samples of commercial fish species. The differences are dramatic, more than 100-fold between the safest and the most dangerous species. The decisive variables: lifespan of the fish, position in the food chain, and geographic origin.
| Fish species | Avg. Hg (ppm) | Burden | Recommendation |
|---|---|---|---|
| Swordfish | ⬛ Very high | Avoid | |
| Shark (incl. spiny dogfish/"Schillerlocke") | ⬛ Very high | Avoid | |
| Large mackerel (king mackerel) | 🟧 High | Avoid | |
| Tuna (canned albacore) | 🟧 Medium-high | Limit (1×/week) | |
| Tuna (canned light) | 🟨 Medium | Limit (2×/week) | |
| Atlantic cod | 🟨 Low-medium | Moderate amounts | |
| Wild salmon (Atlantic/Pacific) | 🟩 Very low | Safe | |
| Sardines | 🟩 Very low | Safe | |
| Mackerel (Atlantic, small) | 🟩 Low | Safe |
Data: FDA Mercury in Commercial Fish 1990–2012 (n=1,300+ samples). EU limits: 0.3 mg/kg for most fish species, 1.0 mg/kg for predatory fish (tuna, shark, swordfish). Small Atlantic mackerel ≠ king mackerel, a common mix-up. ppm = mg/kg fresh weight.
The Faroe-Seychelles controversy, why the studies disagree
Two of the most important studies on prenatal methylmercury exposure reach opposite conclusions, and that is not a measurement error but biologically highly informative.
1,022 children whose mothers regularly ate pilot whale (the main mercury source) were followed from birth. By school age: significant deficits in attention, memory, language, and fine motor skills. At 14 years: persistent impairments. At 22 years: cognitive deficits measurable even at maternal hair levels of 10–20 µg/g, previously regarded as "safe." This study formed the primary data basis for the US EPA reference value of 0.1 µg/kg/day.
Grandjean et al., Neurotoxicol Teratol. 1997; Budtz-Jørgensen et al., Neurotoxicol. 1999779 children of mothers who ate ocean fish (avg. Hg in hair: 6.8 ppm), through age 24, showed no consistent negative neurodevelopmental effects. The decisive difference from the Faroe study: a different mercury source, far more omega-3 fatty acids and selenium in the fish, and barely any PCB contamination (as found in pilot whale). This suggests: it is not mercury alone that decides, but the mercury-to-selenium ratio, and the accompanying substances.
Myers et al., Neurotoxicol. 1997; Davidson et al., Neurotoxicol Teratol. 2017Mercury binds selenium with an affinity orders of magnitude higher than its binding to cysteine. In fish with a positive Se:Hg ratio (i.e., more moles of selenium than mercury), including salmon, sardines, and cod, selenium largely neutralizes the mercury. In fish with a negative ratio (swordfish, pilot whale), this protective buffer is missing. This approach (Selenium Health Benefit Value, HBVSe, Ralston & Raymond) explains why ocean-fish consumers do not necessarily suffer neurological harm despite measurable Hg levels in the blood, and why swordfish can be more dangerous than certain tuna species despite similar Hg values.
Special risk: pregnancy and childhood
The developing nervous system is particularly vulnerable to methylmercury, because neuronal migration, synaptogenesis, and myelination are precisely timed processes that are easily knocked out of rhythm by ion-channel disruption and oxidative stress. The FDA and EFSA recommend, for pregnant and breastfeeding women and for children up to age 12: no swordfish, shark, king mackerel, marlin, or bigeye tuna, and 2–3 servings (225–340 g) of low-mercury fish per week. This recommendation matters, because omega-3 fatty acids from fish are essential for brain development; the mistake would be to avoid all fish.
Lead, the forgotten ubiquity
The calcium-mimicry problem
Lead is so toxicologically dangerous because, biochemically, it mimics calcium. The Pb²⁺ ion has an ionic radius similar to Ca²⁺ and carries the same charge; this opens calcium channels, lead enters cells, activates calcium-dependent signaling pathways in faulty ways, and displaces calcium from bone, neurons, and cardiac muscle cells.
What lead does in the body, a system overview
- Nervous system (children): For every 1 µg/dL increase in blood level: measurable IQ reduction. No lower threshold known. The CDC has progressively lowered its reference value from 60 to 3.5 µg/dL (2021) since 1971, and states: there is no safe blood level for children.
- Cardiovascular system: Lead reduces nitric-oxide bioavailability, raises angiotensin II, and promotes atherosclerosis. Menke et al. (2006, Circulation, n=13,946): hazard ratio 1.55 for cardiovascular mortality at blood Pb ≥3.62 µg/dL vs. <1.94 µg/dL. Lanphear et al. (2018): ~412,000 annual US deaths from lead-related cardiovascular disease.
- Inhibition of hemoglobin synthesis: Lead blocks δ-aminolevulinic acid dehydratase (ALAD) and accumulates neurotoxic ALA precursors, one of the oldest known toxicological effects.
- Bone as silent depot: A 20–30-year half-life means the lead from a childhood exposure in a 1970s old building is still ~50% present in a 50-year-old today. With menopause, fractures, or diseases that involve bone resorption, this lead is remobilized.
- Epigenetic changes: Prenatal lead exposure has been shown to alter DNA methylation patterns in key immune-system and nervous-system genes, effects that have been observed across generations.
The TACT trial (2003–2012, n=1,708 patients after myocardial infarction) showed an 18% reduction in cardiovascular events (HR 0.82, p=0.035) with EDTA chelation. In diabetic patients the effect was dramatic: HR 0.59 (NNT 6.5). The follow-up TACT2 (2024) was negative, presumably because baseline lead levels in the current population have fallen significantly. The TACT data suggest: in people with significant lead body burden, EDTA chelation can reduce cardiovascular risk.
Lamas GA et al. JAMA. 2013;309(12):1241–1250 (TACT) · Lamas GA et al. ACC 2024 (TACT2, preliminary negative)Arsenic, the poison in rice and drinking water
The methylation paradox, why genetics decide
In the body, arsenic is converted by the enzyme AS3MT through a methylation cascade: inorganic arsenic → MMA(III) → DMA(V). The problem: the intermediate MMA(III) (monomethylarsonous acid, trivalent) is more toxic than the original inorganic arsenic, not less. People who eat a lot of arsenic and methylate poorly accumulate this particularly harmful intermediate.
AS3MT gene activity varies enormously between population groups. Indigenous Andean communities, who have consumed arsenic-rich drinking water for generations, carry protective AS3MT polymorphisms at frequencies of 72–76%, possibly the result of evolutionary selection. These variants produce more DMA(V) and less MMA(III), which is associated with lower cancer risk. Folic acid and vitamin B12 are direct regulators of this methylation pathway, an argument for methylation support as a protective strategy.
Cadmium, the silent kidney killer
Kidney toxicity and Itai-itai disease
The organ target of cadmium is the proximal renal tubule. Cadmium-metallothionein complexes are filtered glomerularly and reabsorbed tubularly, where they accumulate up to a critical cortical concentration of about 200 µg/g. The first measurable biomarker is elevated urinary beta-2-microglobulin (>300 µg/g creatinine). Advanced cadmium damage leads to Fanconi syndrome: renal calcium and phosphorus loss, osteomalacia, and osteoporosis.
The best-known historical case: Itai-itai disease in Japan (1950s–70s) in the Jinzū River basin, where industrial cadmium contaminated the groundwater. Affected individuals (mostly postmenopausal women suffering from malnutrition) developed extreme bone pain and multiple spontaneous fractures. 196 officially recognized cases, with many more undiagnosed.
Cadmium directly binds and activates estrogen receptor alpha (ERα) with an affinity comparable to 17β-estradiol; it is a metalloestrogen. In laboratory models, cadmium stimulates estrogen-responsive gene expression, breast-cancer-cell proliferation, and PCOS-like ovarian changes. In epidemiological studies, blood cadmium correlates with elevated breast-cancer risk in postmenopausal women. This has clinical relevance: in patients with unexplained estrogen dominance, cycle disturbances, or hormone-associated cancer risks, cadmium should not be missing from the toxin history.
DMPS and DMSA have no established efficacy in chronic cadmium exposure, and may even increase kidney burden if cadmium is mobilized in larger amounts without being optimally excreted. In acute cadmium poisoning (a rare exception), DMSA can be used immediately after exposure. For chronic exposure, the rule is: smoking cessation is the most effective intervention. Supportively: zinc and calcium competitively inhibit Cd uptake in the gut; an optimized nutrient status reduces biological availability.
Aluminum, the most controversial metal
What is proven, and what is not
The dialysis encephalopathy of the 1970s/80s proves: at high concentrations, aluminum is a potent neurotoxin. Patients who received aluminum-containing dialysate solutions and phosphate binders developed speech and movement disorders, seizures, and dementia. This finding is undisputed. But the neuropathology does not resemble Alzheimer's disease: no amyloid plaques, no tau filaments, no neurodegenerative progression pattern.
Rondeau et al. (PAQUID cohort, 2000): Al >0.1 mg/L in drinking water → relative Alzheimer's risk 2.20 (95% CI: 1.24–3.89). Silicon ≥11.25 mg/L was protective (RR 0.75). Subsequent studies have not consistently replicated this finding. Meta-analyses tend to show elevated aluminum levels in the brain, serum, and CSF of Alzheimer's patients, but causality remains unproven. EFSA and Alzheimer's societies classify the evidence as inconsistent.
Rondeau V et al. Am J Epidemiol. 2000;152(1):59–66 · Lidsky TI. J Occup Environ Med. 2014;56(Suppl 5)Silicon-rich mineral water as a natural detox
Orthosilicic acid in silicon-rich mineral water (≥30 mg/L) forms soluble hydroxyaluminosilicate complexes with aluminum, which are excreted renally. Davenward et al. (2013) gave 15 Alzheimer's patients up to 1 liter daily for 12 weeks: aluminum body burden fell measurably, and 3 of 15 patients showed clinically relevant cognitive improvement. The evidence is preliminary and methodologically limited (small, open-label study, no control group). But the intervention is safe, low-threshold, and inexpensive, which makes it a sensible component of a more comprehensive protocol.
The cocktail effect, why single-substance limits lie
All limit values, for mercury in fish, lead in drinking water, cadmium in foods, are set in isolation. That is regulatorily pragmatic, but biologically potentially dangerous. When several heavy metals are present at the same time, their toxicities do not add up, they multiply.
Schubert et al. (1978, Journal of Toxicology and Environmental Health) combined sublethal doses of mercury and lead in rats: although neither dose alone caused any or hardly any deaths, 100% of the animals died with the combination. This finding is 46 years old and is still not fully reflected in regulation.
More recent data confirm the mechanism: Frontiers in Public Health (2023) showed that Pb/Hg/Cd mixtures in mice produce significantly stronger neurobehavioral impairments than any metal alone, via disruption of dopaminergic and serotonergic systems in the striatum. The ATSDR (US Toxic Substances Agency) notes: arsenic-cadmium-lead combinations show greater-than-additive effects on neurological endpoints.
Patients who once had amalgam, eat tuna regularly, lived in an old building with lead pipes, and smoke or used to smoke, carry a cumulative metal mixture burden that, taken as a whole, may be more toxicologically relevant than any individual measurement suggests. This is an argument for a holistic view and against thinking in terms of single-substance limits.
Typical symptom patterns, what I see in practice
Heavy-metal exposures show no pathognomonic symptoms; that is one of the central diagnostic problems. The complaints overlap with burnout, thyroid disease, autoimmune processes, mold exposure, and chronic stress. What I do: I look at the pattern, not at a single symptom.
Energy & nervous system
- Chronic exhaustion, no restful sleep
- Performance crashes after small efforts
- Brain fog, concentration problems
- Inner restlessness, irritability
- Sleep disturbances, trouble falling asleep
- Cold intolerance without thyroid findings
Muscles & joints
- Diffuse muscle pain without findings
- Migrating joint and tendon pain
- Morning stiffness, cramps
- Slow recovery after exercise
- Muscle tremor, coordination problems
- Carpal-tunnel-like complaints
Gut & detoxification
- Bloating, alternating stools
- New food intolerances
- Paradoxical reactions to antioxidants
- Elevated liver values without clear cause
- Metallic taste in the mouth
- Increased chemical sensitivity
Psyche, hormones & circulation
- Depressive symptoms without psychiatric cause
- Heart palpitations (cardiology unremarkable)
- Blood-pressure swings, dizziness
- Hormonal imbalances without endocrinological findings
- Borderline-elevated kidney values
- "Not quite feeling like myself anymore"
Why the blood test so often lies
"But my mercury blood value was normal." I hear this sentence regularly. And it is usually correct, and at the same time largely meaningless for the question of tissue burden.
Blood is primarily a transport medium, not a storage organ. It shows what is currently circulating, not what is bound in tissue. And of the relevant heavy metals, a large portion is stored in tissue:
Half-lives and storage sites at a glance
Bar width = relative residence time. Blood measurement primarily shows the short-term transport fraction, not the cumulative tissue burden, which is what is toxicologically decisive.
The half-life calculation, why 10 infusions do more than 10 years of waiting
Imagine you had your last amalgam fillings removed at age 30. The fillings are gone, but the mercury that has been deposited in brain tissue over years is still there.
If the half-life of inorganic mercury in the brain is 15–27 years, that means: without active intervention, you would be 45–57 years old before half of it had been naturally eliminated. Until three quarters were gone: another 30–54 years.
With one DMPS infusion, the body excretes more mercury renally in a few hours than in many weeks without intervention. Cumulatively over 8–12 cycles, a portion of the mobilizable tissue burden is actively reduced, the kind that the body alone would only shed over decades. That is not magic. That is pharmacology.
27Diagnostics, what I actually measure
There is no single perfect diagnostic for heavy metals. Each test has a particular informational value, a particular limitation, and a particular clinical context in which it makes sense. That is not a weakness, that is toxicology.
Baseline labs, what I always collect
Complete blood count, kidney function (creatinine, cystatin C, GFR), liver values (AST, ALT, GGT), thyroid (TSH, fT3/fT4 if needed), ferritin/iron, zinc, selenium, magnesium, vitamin D; this baseline status is mandatory before any further metal diagnostics, because it gauges the system's detoxification capacity and prevents other causes from being overlooked.
Spot urine (screening), first orientation
Multi-hour or first-morning urine sample for mercury, lead, cadmium, arsenic, and aluminum if indicated. The German HBM-I values (Federal Environment Agency): Hg 5 µg/L blood, 7 µg/L urine. These values give an initial orientation, but do not rule out significant tissue burdens when the result is normal. Particularly important: arsenic speciation (separate measurement of iAs, MMA, DMA) and the time interval since the last fish meal (≥72h for valid Hg measurement).
DMPS provocation test, the heart of heavy-metal diagnostics
Intravenous administration of DMPS (individually dosed by body weight and kidney function), followed by 4–6 hours of urine collection and measurement of mobilized metals in a specialty laboratory. This test shows what the body releases from the tissue-blood equilibrium under chelator influence, that is, the mobilizable burden, not just the circulating one. Performed according to the protocol of the German Medical Society for Metal Toxicology (AGM). Important: the test is diagnostic, not therapeutic; the provocation infusion does excrete metals, but a structured therapy cycle is something distinct from it. Note: American toxicology societies (ACMT) reject the post-chelator provocation test as a diagnostic instrument because no population-based reference ranges exist. In German integrative medicine it is nonetheless used; I employ it as one component within the clinical context, not as standalone proof.
Urinary porphyrin profile, a functional biomarker
Mercury specifically inhibits the enzyme uroporphyrinogen decarboxylase, which leads to accumulation of precoproporphyrin in urine, a pattern considered highly specific for Hg burden. This test does not measure metal concentration but the biological effect of the metal on the enzyme system. Particularly valuable in patients whose provocation test is borderline but whose clinical picture strongly suggests a metal burden.
MELISA test, immunological reactivity
The Memory Lymphocyte Immunostimulation Assay measures T-cell sensitization to various metals and dental materials. Important: MELISA measures immunological sensitivity, not toxic body burden. These are different questions. A patient can have a high body burden without MELISA reactivity, and vice versa. I use MELISA when autoimmune processes are in the foreground, or when an amalgam removal is being planned and the tolerance of alternative materials needs to be checked.
Hair mineral analysis, limited but specific uses
Hair reflects systemic metal exposure from 1–3 months ago. The main limitation: external contamination from shampoos, hair dyes, and the environment. The EPA and CDC do not recommend hair analysis for clinical decisions. One relevant exception: chronic arsenic exposure, because arsenobetaine from seafood (which distorts urinary tests) does not accumulate in hair. In selected constellations, hair can be useful; as a stand-alone diagnostic test, it is too unreliable.
DMPS: how chelation therapy works physiologically
DMPS (2,3-dimercapto-1-propanesulfonic acid) is no miracle drug. It is a precisely acting molecule with a clearly describable mechanism. Once you understand what DMPS physiologically does, and what the body would do without it, the logic becomes obvious.
Distribution in the extracellular space
DMPS is administered intravenously and quickly distributes through the blood and extracellular space. It barely penetrates the blood-brain barrier, a safety advantage, because deep CNS deposits are not abruptly mobilized. It works where mercury is currently circulating: in the blood, in extracellular fluid, on membrane surfaces.
The pincer-grip principle of chelation
DMPS has two free –SH groups. They clamp the Hg²⁺ ion at two points simultaneously; the resulting ring binding is more stable than any monodentate sulfur group. DMPS successfully competes against the body's own glutathione, cysteine residues, and other thiol biomolecules for the mercury, and wins. The result: a water-soluble, biochemically inert DMPS-Hg complex.
Mobilization from the tissue-blood equilibrium
Mercury in tissues stands in a dynamic equilibrium with blood; a small share is constantly circulating. When DMPS binds and removes the free Hg in blood, this equilibrium shifts: more Hg passes from the tissue depot into the bloodstream and is captured immediately, before it can redeposit. This gradient effect is the actual therapeutic core, active capture, not passive waiting.
Renal excretion in hours instead of decades
The DMPS-Hg complex is water-soluble and renally excretable. It is actively secreted in the tubules and excreted in high concentrations in urine within 4–6 hours. In a single infusion night, the body excretes more mercury than it would without intervention in months. Cumulatively over a complete cycle: a measurable reduction of the mobilizable burden.
Cycles instead of a single dose
A single cycle does not mobilize everything. The tissue releases Hg step by step, which is why we work in cycles with controlled pauses, during which minerals are rebuilt and the system recovers. The amount excreted per infusion typically declines over time, a sign that the mobilizable burden is decreasing.
"The body excretes mercury, but with the efficiency of an hourglass. Chelation therapy is the step that turns the hourglass 90 degrees."
— Dr. Shukri Jarmoukli, Vivecura BerlinChelators compared, pharmacological and natural
There is a fundamental pharmacological difference between systemic chelators and so-called "natural detox agents," and I communicate this difference honestly because it is central to the therapeutic decision.
Zeolite, activated charcoal, chlorella, and pectin act in the gut: they interrupt the enterohepatic cycle and trap metals that are excreted via bile. That is a sensible component, but they do not enter the blood, the extracellular space, or tissues. They do not shift any tissue-blood equilibrium. The pharmacological difference from systemic chelators is fundamental, not gradual. In my practice I use binders as an adjunct, never as a substitute for systemic chelation therapy when the tissue burden is relevant.
What you can expect at Vivecura, in concrete terms
No one-size-fits-all schema. But clear principles that I apply to every patient, individually adjusted, in a sequence that protects the system rather than overwhelming it.
History & system status
- Detailed exposure and symptom history
- Dental and amalgam history, fish-consumption pattern
- Housing and occupational history (old building, industry)
- Previous therapy attempts and reactions
- Bioimpedance analysis (BIA): cellular status
- HRV measurement: autonomic nervous-system status
Diagnostics
- Baseline labs: kidneys, liver, minerals, thyroid
- Spot urine with metal profile (screening)
- DMPS provocation test per AGM protocol
- Porphyrin profile if appropriate (functional Hg marker)
- MELISA if autoimmune suspicion or planning amalgam removal
- Selenium, zinc, glutathione (antioxidant capacity)
Preparation & chelation cycles
- Build up minerals and glutathione (4–6 weeks)
- Stabilize gut and liver, elimination must work
- DMPS infusions, individually dosed, 8–12 cycles
- Mineral monitoring after each infusion
- Cyclical pauses for regeneration and substitution
- Tracking of excretion amounts over time
Follow-up & regeneration
- Repeat provocation: how has the burden changed?
- IV nutrient infusions: vitamin C, glutathione, B-complex
- Phosphatidylcholine for neurotoxic burden
- Nutritional and lifestyle optimization
- Video consultations possible for follow-up and adjustment
- Honest discussion: another cycle, or close out?
Over years I have made a consistent observation: even in patients whose spontaneous urinary and blood mercury values were entirely unremarkable, post-DMPS urine samples show elevated mercury excretion in a notable number of cases. Under the influence of a chelator, the body releases mercury that it would not mobilize on its own.
One particularly striking case: Markus, 47, Berlin. Persistent exhaustion after a COVID infection, elevated liver enzymes (ALT 62 U/L), brain fog for 7 months. Spontaneous Hg unremarkable. Amalgam removed 18 years earlier. Chelator provocation test: clearly elevated mercury excretion. After 8 cycles over 6 months with accompanying mineral monitoring: ALT normalized (34 U/L), subjective improvement in cognition, and noticeably better sleep quality.
I communicate this transparently: this is a clinical observation, not a randomized trial. Causality cannot be proven here. But the pattern, Hg burden despite long-removed amalgam, measurable excretion under chelator, clinical improvement over the course, is consistent enough in my practice to take this component seriously.
Heavy metals in the system, the link to my other special focus areas
Heavy-metal exposures rarely come alone. They interact with the gut (impaired elimination), with mold toxins (blocked detoxification enzymes), and with the nervous system (neuroinflammation, which limits psychiatric treatments). My four special focus areas are not coincidence, they are a system.
Heavy metals
Long-term storage, tissue burden, chelation therapy
this areaGut Reset
Metal elimination via bile and stool, without a healthy gut there's no efficient detoxification cycle
Mold
Mycotoxins block glutathione synthesis and metallothioneins; with concurrent mold exposure, heavy-metal detoxification deteriorates
Ketamine
Neurotoxic heavy-metal burden can limit the success of psychiatric treatments; reduce the toxin load, then a window for healing opens
Evidence overview, what we know and what we don't
| Statement | Evidence level | Limitation |
|---|---|---|
| Amalgam releases Hg vapor | Strongly supported | Causal harm in healthy adults at the group level not proven |
| MeHg from fish damages the nervous system prenatally | Human studies (Faroe) | Seychelles study contradicts; selenium protection as a possible explanation |
| Genetic vulnerability (CPOX4, MT, SLC6A4) | RCT data (NIH) | Applies to genetically defined subgroups, not all |
| Hg half-life in brain: many years | Toxicokinetic models | Direct in vivo measurement in humans difficult; estimates 15–27 years |
| Lead: no safe threshold | CDC, human studies | IQ effects already detectable below 5 µg/dL; consensus opinion |
| Lead-cardiac risk (TACT) | 1 positive RCT, 1 negative | TACT2 negative, presumably due to lower baseline lead levels |
| Arsenic: IARC Group 1 carcinogen | Established (human) | Skin, lung, bladder; primarily with high drinking-water exposure |
| Cd: kidney damage / hormonal effect | Human / in vitro mechanism | Kidney: human studies solid. Estrogen effect: in vitro well established, human limited |
| Al: Alzheimer's link | Epidemiology inconsistent | Dialysis encephalopathy proves neurotoxicity, direct Alzheimer's causality unproven |
| DMPS mobilizes Hg renally | Pharmacologically supported | Extent of tissue mobilization individually variable |
| Chelation therapy in chronic amalgam exposure | Clinical experience | Grandjean 1997 RCT (n=50) showed no superiority in mild exposure; larger RCTs lacking |
| Cocktail effect (Hg + Pb synergy) | Animal experiment (Schubert 1978) | Human dose extrapolation still incomplete; barely reflected in regulation |
A story from my family that brings it all to a point
My aunt is a dentist. For more than 15 years she has suffered from Hashimoto's thyroiditis, severe hormonal complaints, weight gain despite diets, massive food intolerances, and chronic exhaustion. She has truly tried everything. Dietary changes, hormone therapies, elimination diets, supplement protocols. Brief improvements, but never a real turnaround. Her body seemed to sabotage whatever she tried.
For years I had voiced the suspicion that heavy metals could be playing a role. As a dentist she had had daily contact with amalgam for decades. Grinding, removing, placing. Even with protective measures, the exposure during this work is considerable. Mercury vapor is invisible. And it accumulates.
Her husband is the chief physician of a hematology-oncology clinic in the United States. He is brilliant, experienced, and deeply rooted in conventional medicine. For five years he politely smiled at my suspicion. Heavy metals, functional medicine, DMPS tests. He listened, nodded politely, and left it at that.
Then my aunt decided to take the DMPS provocation test. The results were unambiguous: exceptionally high mobilizable mercury amounts. A burden built up over decades of occupational exposure that no standard blood test had ever shown.
She began chelation therapy. What happened afterwards surprised everyone, perhaps her most of all. The weight that had not yielded to any diet for 15 years began to fall. Energy returned. The intolerances eased. She feels more alive than she has in years.
Her husband, the oncologist, no longer laughs at me. He had himself examined and treated through functional medicine. He is slowly letting go of the idea that conventional diagnostics captures all relevant burdens. First the proof, then the change. That is human. And I understand it.
What I take away from this story: not every cause is recognized with the tools you are used to. Sometimes you need a different question to find a new answer.
Could this be relevant for you? An aid to self-assessment.
What follows is not a diagnosis and is no substitute for a medical history. It is an honest invitation to pause and reflect. Heavy metals show no pathognomonic symptoms. They rarely surface as a clear cause. But they can act for years in the background as silent contributors, without anyone ever asking about them.
I think the following people should seriously consider whether heavy-metal diagnostics would make sense for them. Not as alarmism. As an informed decision.
Group 1: exposures many people have forgotten
- Amalgam fillings, current or past: You had amalgam fillings, perhaps removed 10, 15, or 20 years ago. The mercury isn't gone just because the filling is gone. The half-life in the brain is up to 27 years.
- Occupational amalgam exposure: You are or were a dentist, dental technician, or dental assistant. Years of contact with amalgam during placement and removal mean an exposure that goes well beyond normal, even with protective measures.
- Regular consumption of tuna or swordfish: Anyone who eats tuna two or three times a week can build up a relevant methylmercury burden over months and years without noticing.
- Old building, lead pipes, or lead paint: You live in a building constructed before 1970. You know the water pipes are made of lead, or you suspect they are. Berlin's old buildings are particularly relevant here.
- Smoking, current or past: Cadmium accumulates in the kidney with a half-life of 10 to 30 years. Anyone who has smoked carries this burden for a long time, without knowing it.
- Regular rice consumption, especially rice milk or rice cakes: Arsenic preferentially accumulates in rice plants. Anyone who eats rice as their main grain should have their arsenic status checked at least once.
Group 2: symptoms without a satisfying explanation
- Brain fog that won't go away: Mentally you feel as if behind glass. Concentration problems, word-finding difficulties, a head that feels as if in mist. And every blood test was normal.
- Chronic exhaustion without a clear cause: You sleep eight hours and still aren't rested in the morning. Small efforts exhaust you out of all proportion. Thyroid, complete blood count, all unremarkable.
- Hormonal imbalances that fail to respond lastingly to any therapy: Cycle disturbances, PMS, unexplained weight gain, estrogen dominance with no clear endocrinological cause. Cadmium and zearalenone act as metalloestrogens and can directly disrupt the hormonal system.
- Thyroid disorders, especially Hashimoto's: Mercury directly attacks the selenoenzymes needed for thyroid-hormone activation. There is no proven causality. But the mechanistic plausibility is great enough that, in cases of Hashimoto's, I always ask about the heavy-metal history.
- Autoimmune diseases of any kind: Rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel diseases. Heavy metals can act as chronic triggers for immune activation. No physician can guarantee you that they play a role. But no physician can guarantee you that they don't, without having measured.
- Migrating muscle and joint pain without orthopedic findings: Diffuse pain that doesn't really belong anywhere. MRI unremarkable. Rheumatoid factor negative. No inflammatory finding. And yet this pain.
- Mental health problems that don't respond stably to any classical therapy: Depression, anxiety disorders, emotional instability, a nervous system that seems permanently on alert. When neurobiological toxicity destabilizes the foundation, psychotherapeutic and pharmacological treatments can only do so much.
- Kidney values that remain borderline for years: Slightly elevated creatinine, a slowly declining GFR with no clear cause. Cadmium preferentially attacks the proximal renal tubules, for years without symptoms.
- Intolerances that keep adding up: Food intolerances that slowly expand. A body that reacts to more and more things. Heavy metals can destabilize the gut barrier and chronically activate the immune system, which prepares the ground for intolerances.
- Therapy resistance as a pattern: You have tried a lot. You have had many diagnoses. Many things helped briefly, but nothing took hold lastingly. For me, this is one of the strongest clinical clues. Not because heavy metals are always the cause, but because they can sabotage other therapies as a silent background load.
I consider it medically defensible and sensible to initiate structured heavy-metal diagnostics for anyone who suffers from one or more chronic illnesses, who has demonstrably been exposed to relevant exposures, or who, despite solid therapy attempts, has not achieved stable improvement. Not as the only answer. As one component of a more complete picture. The question is not: "Is it heavy metals?" The question is: "Have we ever sufficiently checked?"
These questions do not replace a medical history or laboratory diagnostics. They are an aid to orientation, not a diagnosis. Not everyone with exhaustion has a heavy-metal burden. And a heavy-metal burden does not automatically explain all symptoms. What counts is the overall clinical context. That is exactly what the initial consultation is for.
Let's look at the complete picture together.
In the first conversation I listen. Without labs, without a checklist. Then we decide together which diagnostics will bring genuinely new information, and which path is right for you.
Book an appointment at VivecuraScientific sources
- DeRouen TA et al. Neurobehavioral effects of dental amalgam in children (Casa Pia Trial). JAMA. 2006;295(14):1644–1652.
- Bellinger DC et al. Neuropsychological and renal effects of dental amalgam in children. JAMA. 2006;295(14):1623–1632.
- Woods JS et al. Genetic polymorphisms affecting susceptibility to mercury neurotoxicity (Casa Pia substudy). Neurotoxicology. 2014;44:242–249.
- Ajsuvakova OP et al. Sulfhydryl groups as targets of mercury toxicity. Coord Chem Rev. 2020;417:213343.
- Grandjean P et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury (Faroe). Neurotoxicol Teratol. 1997;19(6):417–428.
- Myers GJ et al. Seychelles Child Development Study (Outcome 66 months). Neurotoxicol Teratol. 1997;19(6):401–416.
- Davidson PW et al. Neurodevelopmental outcomes in Seychelles at age 22 and 24. Neurotoxicol Teratol. 2017;62:69–76.
- Ralston NVC, Raymond LJ. Mercury's neurotoxicity is characterised by its disruption of selenium biochemistry. Biochim Biophys Acta. 2018;1862(11):2405–2416.
- FDA. Mercury Levels in Commercial Fish and Shellfish 1990–2012. fda.gov.
- EU Regulation 2023/915 on maximum levels for contaminants in food.
- Rooney JPK. The retention time of inorganic mercury in the brain, systematic review. Toxicol Appl Pharmacol. 2014;274(3):425–435.
- Charkiewicz AE et al. Mercury exposure and health effects. Int J Mol Sci. 2025;26(5):2326.
- Menke A et al. Blood lead below 0.48 µmol/L and mortality among US adults. Circulation. 2006;114(13):1388–1394.
- Lanphear BP et al. Low-level lead exposure and mortality in US adults. Lancet Public Health. 2018;3(4):e177–e184.
- Needleman HL et al. IQ and blood lead levels, pooled international analysis. Environ Health Perspect. 2005;113(7):894–899.
- Lamas GA et al. Effect of disodium EDTA chelation regimen on cardiovascular events (TACT). JAMA. 2013;309(12):1241–1250.
- Lamas GA et al. TACT2, EDTA Chelation in Diabetic Post-MI Patients (negative). ACC. 2024.
- IARC Monographs. Arsenic and arsenic compounds. IARC Monogr Eval Carcinog Risks Hum. 2012;100C.
- Vahter M. Mechanisms of arsenic biotransformation (AS3MT). Toxicology. 2002;181–182:211–217.
- EFSA. Arsenic in food, Scientific Opinion. EFSA Journal. 2009;7(10):1351.
- Stoica A et al. Cadmium activates estrogen receptor alpha. Cancer Res. 2000;60(20):5844–5849.
- Järup L, Akesson A. Current status of cadmium as an environmental health problem. Toxicol Appl Pharmacol. 2009;238(3):201–208.
- EFSA. Cadmium dietary exposure in the European population. EFSA Journal. 2012;10(1):2551.
- Rondeau V et al. Aluminum and silica in drinking water and the risk of Alzheimer's disease. Am J Epidemiol. 2000;152(1):59–66.
- Lidsky TI. Is the aluminum hypothesis dead? J Occup Environ Med. 2014;56(Suppl 5):S73–S79.
- Davenward S et al. Silicon-rich mineral water as a non-invasive test of the aluminum hypothesis in Alzheimer's disease. J Alzheimers Dis. 2013;33(2):423–430.
- Schubert J et al. Combined effects in toxicology, cadmium, mercury, and lead. J Toxicol Environ Health. 1978;4(5–6):763–776.
- Grandjean P et al. Chelating treatment in patients with symptoms attributed to amalgam fillings, RCT. Occup Environ Med. 1997;54(3):180–188.
- DMPS (Dimaval®) prescribing information. Heyl Chem.-pharm. Fabrik GmbH, Berlin. BfArM approval since 1996.
- Aposhian HV et al. Vitamin C, glutathione, lipoic acid did not decrease brain/kidney mercury in rats. J Toxicol Clin Toxicol. 2003;41(4):491–500.
- EU Council. Council Directive 2020/2184 on drinking water quality (Pb limit 5 µg/L). 2020.
- Pamphlett R, Bishop DP. Mercury in neurons in Parkinson's disease regions. PLoS One. 2022;17(1):e0262464.
- Cheng H et al. Heavy Metals Toxicity: Mechanism, Health Effects, and Therapeutic Interventions. MedComm. 2025. DOI: 10.1002/mco2.70241.